Table 3. Neutralization and... | American Society of Hematology

Table 3.

Neutralization and Immunoprecipitation Assays of Plasmas From 11 Hemophilic Inhibitors Treated Only With Recombinant Factor VIII

Inhibitor	% Neutralization by FVIII Region			Epitopes of Major	Immunoprecipitation of
No.	A2	C2	LCh	Inhibitors	A2	C2
				Domain(s)
R7611	74	27	23	A2, C2	+	+
R1911	37	74	76	A2, C2	+	+
R1113	85	26	30	A2, C2	+	+
R3511	49	41	34	A2, C2	+	+
R7717	≤5	≤10	89	AR3-A3-C1	+	+
R2113	27	54	76	A2, C2, AR3-A3-C1	+	+
K66	≥95	≤5	≤5	A2	+	+
K126	68	51	>44	A2, C2	+	+
K129	24	26	78	A2, C2, AR3-A3-C1	+	+
K147	37	43	72	A2, C2, AR3-A3-C1	+	+
K184	28	51	65	A2, C2, AR3-A3-C1	+	+

Inhibitor	% Neutralization by FVIII Region			Epitopes of Major	Immunoprecipitation of
No.	A2	C2	LCh	Inhibitors	A2	C2
				Domain(s)
R7611	74	27	23	A2, C2	+	+
R1911	37	74	76	A2, C2	+	+
R1113	85	26	30	A2, C2	+	+
R3511	49	41	34	A2, C2	+	+
R7717	≤5	≤10	89	AR3-A3-C1	+	+
R2113	27	54	76	A2, C2, AR3-A3-C1	+	+
K66	≥95	≤5	≤5	A2	+	+
K126	68	51	>44	A2, C2	+	+
K129	24	26	78	A2, C2, AR3-A3-C1	+	+
K147	37	43	72	A2, C2, AR3-A3-C1	+	+
K184	28	51	65	A2, C2, AR3-A3-C1	+	+

Descriptions are as in Table 1. The PUPs are designated by R when Recombinate was used as the therapeutic fVIII product or K for Kogenate. The average maximal neutralization by heavy chain plus LCh polypeptides was 103% ± 9.9% SD.

View Large

This Feature Is Available To Subscribers Only